These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15472249)

  • 1. European Commission wants drug companies to test products for use in children.
    Watson R
    BMJ; 2004 Oct; 329(7470):818. PubMed ID: 15472249
    [No Abstract]   [Full Text] [Related]  

  • 2. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 3. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G
    Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract]   [Full Text] [Related]  

  • 4. Researchers see a need for speed in EU trial approvals.
    Cressey D
    Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580
    [No Abstract]   [Full Text] [Related]  

  • 5. Lessons from Eprex for biogeneric firms.
    Louët S
    Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
    [No Abstract]   [Full Text] [Related]  

  • 6. In the wake of the Mediator scandal: some progress in France, but apathy at the European level.
    Prescrire Int; 2012 Apr; 21(126):110. PubMed ID: 22515143
    [No Abstract]   [Full Text] [Related]  

  • 7. EU directive on clinical trials penalizes small sponsors.
    Meldolesi A
    Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
    [No Abstract]   [Full Text] [Related]  

  • 8. Path to approval proves rocky for copycat biodrugs.
    Wadman M
    Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 10. Intellectual property. Fixing the legal framework for pharmaceutical research.
    Knowles SM
    Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
    [No Abstract]   [Full Text] [Related]  

  • 11. [Approval of drugs by national and European agencies--sequelae for the pharmaceutical industry].
    Zierenberg O
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):596-600. PubMed ID: 9527448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Bonne Année", "Gutes Neues Jahr"? Will 2007 be a "Happy New Year" for children's medicines in Europe?
    Stephenson T
    Arch Dis Child; 2007 Aug; 92(8):661-3. PubMed ID: 17642477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Be careful on the Internet].
    Jensen JW
    Ugeskr Laeger; 2006 Sep; 168(38):3189. PubMed ID: 17026889
    [No Abstract]   [Full Text] [Related]  

  • 14. [Experiences of the drug approval processes in the European Union].
    Pasanen M; Toivonen M
    Duodecim; 2000; 116(24):2817-22. PubMed ID: 12077887
    [No Abstract]   [Full Text] [Related]  

  • 15. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

  • 18. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
    Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
    Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
    [No Abstract]   [Full Text] [Related]  

  • 19. The World Health Organization's prequalification program and its potential effect on data exclusivity laws.
    Childs DW
    Food Drug Law J; 2005; 60(1):79-97. PubMed ID: 15940855
    [No Abstract]   [Full Text] [Related]  

  • 20. Whistleblower vows to fight on.
    Dyer C
    BMJ; 2004 Jan; 328(7433):187. PubMed ID: 14739181
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.